5th Mar 2015 11:27
LONDON (Alliance News) - Vectura Group PLC said Thursday that the US Food and Drug Administration has accepted for review new drug applications for its QVA149 and NVA237 for the long-term maintenance treatment of chronic obstructive pulmonary disease.
This triggers USD12.5 million and USD7.5 million in milestone payments for Vectura.
It submitted the filings in the last quarter of 2014.
Shares in Vectura are trading up 1.8% at 152.00 pence Thursday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
VEC.L